Stockscreener 앱 받기
64.06
2.70%
-2.04
Instil Bio Inc 주식(TIL)의 최신 뉴스
The time has not yet come to remove your chips from the table: Instil Bio Inc (TIL) - SETE News
Financial Metrics Unveiled: Instil Bio Inc (TIL)’s Key Ratios in the Spotlight - The Dwinnex
Here's Why Everyone's Talking About Summit Therapeutics - MSN
This is why everyone is talking about Summit TherapeuticsTHE BHARAT EXPRESS NEWS - The Bharat Express News
Here's Why Everyone's Talking About Summit Therapeutics - The Motley Fool
Instil Bio stock target raised by H.C. Wainwright on cancer drug outlook - Investing.com
Baird retains price target, outperform rating on Instil Bio shares - Investing.com India
Crude Oil Surges Over 1%; Instil Bio Shares Plunge - Benzinga
Instil Bio Inc (TIL) Stock: A Year of Highs and Lows in the Market - The InvestChronicle
Instil Bio Stock Skyrockets 641% in One Week: Here's Why - Yahoo Finance
Instil Bio stock target raised by H.C. Wainwright on cancer drug outlook - Investing.com India
Do investors need to be concerned about Instil Bio Inc (TIL)? - US Post News
Instil Bio Outlines Oncology Strategy and Collaborative Efforts - TipRanks
Instil Bio and ImmuneOnco Announce Global Registrational Strategy for PD-L1xVEGF Bispecific Antibody, SYN-2510/IMM2510, in Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer - Yahoo Finance
Up More Than 500% in 2024. Can Instil Bio Keep Rocketing Higher? - sharewise
Up More Than 500% in 2024. Can Instil Bio Keep Rocketing Higher? - The Motley Fool
Baird ups Instil Bio shares target as PD-1/L1xVEGF space gains momentum - Investing.com India
Summit lifts Instil, BioNTech on Merck beating data (NASDAQ:SMMT) - Seeking Alpha
Instil Bio: PD-L1/VEGF Bispecific Targeting With Unique Enhancements (TIL) - Seeking Alpha
Instil Bio surges after Baird target calls for shares tripling - TipRanks
(TIL) On The My Stocks Page - Stock Traders Daily
Instil Bio’s Stock Price Target (NASDAQ: TIL) Get’s A Big Uplift From Baird - AskTraders
Instil Bio price target raised to $180 from $32 at Baird - TipRanks
Baird ups Instil Bio shares target as PD-1/L1xVEGF space gains momentum - Investing.com Australia
Baird ups Instil Bio shares target as PD-1/L1xVEGF space gains momentum - Investing.com
Baird ups Instil Bio shares target as PD-1/L1xVEGF space gains momentum - Investing.com UK
H.C. Wainwright raises share target for Instil Bio by US$15 - Mugglehead
H.C. Wainwright raises Instil Bio shares target with Buy rating - Investing.com
Instil Bio Surges After Another Price-Target Boost - MarketWatch
Instil Bio (TIL) Surges on Promising Cancer Therapy Licensing Deal - BP Journal
Summit Therapeutics Secures $235 Million in Funding from Leading Biotech Investors - BP Journal
H.C. Wainwright raises Instil Bio shares target with Buy rating - Investing.com India
H.C. Wainwright raises Instil Bio shares target with Buy rating By Investing.com - Investing.com UK
Exact Sciences To Rally Around 33%? Here Are 10 Top Analyst Forecasts For Thursday - Benzinga
A stock that deserves closer examination: Instil Bio Inc (TIL) - US Post News
Private equity firms are Instil Bio, Inc.'s (NASDAQ:TIL) biggest owners and were rewarded after market cap rose by US$52m last week - Yahoo Finance
TIL’s Stochastic Averages Dip: Analyzing Instil Bio Inc’s Stock Performance - The InvestChronicle
United States shares higher at close of trade; Dow Jones Industrial Average up 1.20% - MSN
Instil Bio stock soars to 52-week high, hits $16.4 - Investing.com
Instil Bio shares positive on external trial data, Baird maintains price target - Investing.com
Instil Bio Shares Rise After Exiting Operations in Manchester, U.K. - MarketWatch
Instil Bio announces closure of UK operations - Investing.com
Instil Bio Exiting Manchester, UK, Operations and Eliminating Workforce - MarketWatch
Instil Bio stock soars to 52-week high, reaches $13.95 - Investing.com India
Instil Bio stock soars to 52-week high, reaches $13.95 By Investing.com - Investing.com Canada
Applied DNA Sciences Inc. (NASDAQ: APDN): Expanding Horizons in DNA Technology and Clinical Testing - BP Journal
Learn to Evaluate (TIL) using the Charts - Stock Traders Daily
Instil Bio Presents Latest Updates with Investor Disclaimer - TipRanks
TIL Stock Earnings: Instil Bio Beats EPS for Q2 2024 - MSN
TIL Stock Earnings: Instil Bio Beats EPS for Q2 2024 - InvestorPlace
Instil Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Instil Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update - Yahoo Finance
$2B+ at stake for Immuneonco in rights deal with Instil Bio - BioWorld Online
Week In Review: ImmuneOnco Out-Licenses 2 Antibodies In $2 Billion Deal - Seeking Alpha
TILInstil Bio, Inc. Latest Stock News & Market Updates - StockTitan
Sino-American deal in immuno-oncology - The Pharma Letter
Instil Bio inks deal with ImmuneOnco for antibody therapies - Investing.com
Instil refills pipeline in $2B biobucks deal with China's ImmuneOnco for 2 cancer assets - Fierce Biotech
Instil Bio and ImmuneOnco Announce License and Collaboration Agreement for Development of IMM2510, a Potentially Best-in-Class PD-L1xVEGF Bispecific Antibody, and IMM27M, a Novel Next-Generation Anti-CTLA-4 Antibody - ForexTV.com
Instil Bio and ImmuneOnco Announce License and - GlobeNewswire
Instil Bio and ImmuneOnco Announce License and Collaboration Agreement for Development of - The Bakersfield Californian
Instil Bio and ImmuneOnco Announce License and Collaboration Agreement for Development of IMM2510, a Potentially Best-in-Class PD-L1xVEGF Bispecific Antibody, and IMM27M, a Novel Next-Generation Anti-CTLA-4 Antibody - StockTitan
Long Term Trading Analysis for (TIL) - Stock Traders Daily
Instil Bio Shares Surge Following Rental Agreement with AstraZeneca - Morningstar
Instil Bio Shares Surge Following Rental Agreement with AstraZeneca - MarketWatch
Eliem Therapeutics EVP sells over $730k in company stock By Investing.com - Investing.com
1.16%
2.02%
자본화:
|
볼륨(24시간):